2023 was a challenging year for the biotech industry. We collaborated with a diverse set of clients, each at varying stages of their fundraising endeavors. As we reflect on the past year, we’d like to take a moment to highlight the impressive milestones our clients have reached.

Lexeo Therapeutics Lexeo is a public company focused on developing gene therapies for rare diseases. We have actively supported Lexeo’s journey from private funding rounds to their public debut this year. Our work included creating investor slides and MOA illustrations to developing their websites, patient education and recruitment materials.

Inhibrx Therapeutics Inhibrx is a publicly traded company with multiple next-generation biologics for various diseases. We supported them this year on various business development, investor, and patient communication projects. We applaud their promising results for INBRX 101, a recombinant Alpha -1 antitrypsin protein, and we will continue to support their growth in 2024.

TScan Therapeutics TScan is a clinical-stage public company working on T-cell therapies. We’re proud to have helped this company effectively communicate their complex science and showcase their platform clearly and concisely to investors. We look forward to continue working with them in 2024.

ALX Oncology ALX Oncology is a publicly traded company with lead drug candidate Evorpacept, a CD47 blocker. This year, we supported their business development team in achieving various milestones and helped refine their corporate story to highlight the unique differentiation of Evorpacept. We congratulate ALX Oncology on the positive Phase 2 interim data, and we look forward to continuing to support them in the next year.

DiaMedica Therapeutics Diamedica, a public company, aims to improve acute ischemic stroke (AIS) outcomes with investigational drug candidate DM199. We clarified the novel mechanism of DM199 via MOA illustrations and animated video to help Diamedica improve communications with investors and investigators. We wish them the best of luck with the ongoing Phase 2 / 3 clinical trial.

Dr H. Michael Shephard We had the privilege of working with Dr. H. Michael Shephard, who played a pivotal role in the discovery of Herceptin. We extend our heartfelt wishes for success in his new venture, Enosi Therapeutics.

venBio venBio is an exceptional life sciences investment firm that invests in early-stage companies. We are honored that they continue to trust us to work with their portfolio companies. This year, they asked us to design and launch their website. Working with such a reputable company is an honor, and we are excited to continue working with venBio and their portfolio companies.

ReCode Therapeutics Recode is a private company focusing on novel lipid nanoparticle (LNP) delivery mechanisms with a pipeline targeting rare diseases. We helped them clarify their story to investors in a recent private round of funding—a big congratulations to ReCode on closing the extension of series B. We look forward to continuing to support them in 2024.

Repare Therapeutics Repare is a public company with an extensive pipeline of synthetic lethality-based therapeutics for precision oncology. We’ve been updating their scientific slides throughout the year. We congratulate Repare for their SNIPRx platform advancements and collaboration with Roche for Camonsertib.

Sanford Laboratories We are thrilled to have contributed to the growth of this non-profit biomedical research institution. A couple of years back, we helped them communicate their vision to an investor – Danny Sanford. This year, we are actively involved in shaping their brand, developing communications materials, and helping them grow. We congratulate them on the launch of their scientific hub.

Tallac Therapeutics Tallac operates as a privately held company within the oncology space. Since their inception, we have supported them with various services such as website updates, scientific posters, and managing their LinkedIn page to attract potential investors. We are thrilled to see their success, especially with the recent announcement of their initial clinical data.

Axent Biosciences Axent Biosciences is an early-stage company that is developing next-generation stem cell therapies. They created a proprietary platform that allows them to scale cell manufacturing, which is unprecedented. Our team created a new brand for Axent and distilled the messaging to create a compelling investor deck. We are excited about the future of stem cell therapies and will be following Axent’s progress.

We take great pleasure in witnessing our client’s growth and success as they progress in their drug development journey. Into the new year, we wish them all the greatest achievements in each stage of their ventures.

Are you preparing for a significant milestone next year and need a reliable partner to help you succeed?

Contact us to work together and get you on track to achieving your 2024 milestones.